Literature DB >> 9081958

Combination therapy in Kala-azar.

N K Singh1, T K Jha, I J Singh, S Jha.   

Abstract

128 untreated cases of Kala-azar were divided in 4 equal groups of 32, Group A was treated with Sodium Stibogluconate (SSG) in the dose of 20 mg/kg/body wt. for 30 days. Group B was treated SSG plus allopurinol in the dose of 20 mg/kg/body wt. orally in divided dosage for 30 days. Group C received SSG plus Ketoconazole 600 mg orally in divided dosage for 30 days. Group D in addition to SSG also received levamisole in single oral daily dose of 13 mg/kg/body wt. for 30 days. Response of Group B, C and D was compared to Group A. Results from this study revealed combination of allopurinol with SSG to be statistically not superior to SSG alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9081958

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  5 in total

1.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

3.  Pharmacotherapeutic options for visceral leishmaniasis-current scenario.

Authors:  Krishna Pandey; Prabhat Kumar Sinha; Vidyanand Ravi Das; Sanjiva Bimal; Shubhankar K Singh; Pradeep Das
Journal:  Clin Med Pathol       Date:  2009-01-23

4.  MANAGEMENT OF KALA AZAR - AN UPDATE.

Authors:  S P Kalra; A Bahl; Lt Col Pc Sanchetee; S K Dham
Journal:  Med J Armed Forces India       Date:  2017-06-26

5.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.